Product Code: 02-ONCOP-26
From £655.00 Early Bird
Early Bird Deadline: 31/01/2026
Deadline to order: 28/02/2026
This EQA scheme is offered to help laboratories using high through put technologies (e.g., NGS, MassArray etc.) to accurately validate assay sensitivity and specificity. For specific tumour types, please register for the relevant scheme (e.g., Lung, Melanoma, Colorectal, Ovarian, Breast, Prostate, Pancreas). High quality reference materials are provided covering a range of genes with variants with ddPCR quantified allelic frequencies.
For example, variants in the BRAF, EGFR, ERBB2, IDH2, PIK3CA, MET, KIT, KRAS, NRAS and AKT1 genes.
Array based, NGS, Panel testing, PCR based, Whole exome sequencing, Whole genome sequencing
English
FFPE
Yes
June 2026
June - August 2026
December 2026 - January 2027
You can complete purchase on our secure partner site.
The Oncogene Panel EQA scheme is designed to tests a laboratory’s ability to detect a range of clinically significant variants in the context of precision medicine for cancer e.g. activating/driver mutations and resistance mutations. Genotyping only scheme.
Three mock clinical cases with matching artificial paraffin embedded (FFPE) reference materials (designed to simulate real patient samples). Two 15um thick FFPE sections per case are provided.
NOTE: Samples provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
Variant allele frequencies of the artificial FFPE reference materials have been validated using ddPCR.
There is an option to purchase additional sets of samples at the time of scheme purchase. For example, for laboratories requiring more sample material to complete testing of the EQA. There is a maximum of 3 x additional sets of samples per participant.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
For each case, participants are expected to test these samples using their routine methodology and return the analytical result (genotyping) only. These samples are not suitable for an RNA-based methodology only.
If you do not routinely test a particular marker/gene, then it is acceptable not to submit results for it i.e., testing for all of the genes shown above is NOT required to participate.
Reporting must be restricted to clinically relevant variants and should not include common polymorphisms or minor risk altering alleles. Justification and evidence for the inclusion of reported variants will be requested when reporting results to EMQN. Laboratories are expected to provide information about their test scope and the technical and clinical limitations of their assays to enable accurate assessment.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.